Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Hatfaludi, Tamás ^a   Al Hasani, Keith ^a,d   Gong, Lan ^a   Boyce, John D ^a   Ford, Mark ^b   Wilkie, Ian W ^c   Quinsey, Noelene ^a   Dunstone, Michelle A ^a   Hoke, David E ^a   Adler, Ben ^a  

^a MONASH UNIVERSITY   (Australia)

^b CSIRO   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d CENTRE DE BIOCHIMIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIN; CHOLERA VACCINE; MEMBRANE PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL VIRULENCE; CELL SURFACE; CHICKEN; CONTROLLED STUDY; FEMALE; FOWL CHOLERA; HIGH THROUGHPUT SCREENING; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INFECTION PREVENTION; INFECTION RESISTANCE; MOLECULAR CLONING; MOUSE; NONHUMAN; PASTEURELLA MULTOCIDA; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; SURVIVAL RATE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHICKENS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; MICE; MUTANT PROTEINS; PASTEURELLA INFECTIONS; PASTEURELLA MULTOCIDA; POULTRY DISEASES; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); GALLUS GALLUS; MUS;

EID: 84863630876     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039973     Document Type: Article

References (58)

1. Hansson M, Nygren PA, Stahl S, (2000) Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem 32 (Pt 2): 95-107.
2. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
3. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, et al. (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69: 1593-1598.
4. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
5. Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, et al. (2001) Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19: 4135-4142.
6. Boyce J, Harper M, Wilkie I, Adler B, (2009) Pasteurella. In: Prescott JF, editors. editor. Pathogenesis of Bacterial Infections in Animals. 4th ed. Iowa, USA: Blackwell Publishing.
7. Carter GR, (1967) Pasteurellosis: Pasteurella multocida and Pasteurella hemolytica. Adv Vet Sci 11: 321-379.
8. Heddleston KL, Gallagher JE, Rebers PA, (1972) Fowl cholera: gel diffusion precipitin test for serotyping Pasteruella multocida from avian species. Avian Dis 16: 925-936.
9. Boyce J, Lo RY, Wilkie I, Adler B, (2004) Pasteurella and Mannheimia. In: Gyles CL, Prescott JF, Songer JG, Thoen CO, editors. pp. 273-294 editors. Pathogenesis of Bacterial Infections in Animals. 3rd ed. Oxford, UK: Blackwell Publishing.
10. Adler B, Chancellor R, Homchampa P, Hunt M, Ruffolo C, et al. (1996) Immunity and vaccine development in Pasteurella multocida infections. J Biotechnol 44: 139-144.
11. Verma R, Jaiswal TN, (1997) Protection, humoral and cell-mediated immune responses in calves immunized with multiple emulsion haemorrhagic septicaemia vaccine. Vaccine 15: 1254-1260.
12. Magyar T, King VL, Kovacs F, (2002) Evaluation of vaccines for atrophic rhinitis-a comparison of three challenge models. Vaccine 20: 1797-1802.
13. Hopkins BA, Huang TH, Olson LD, (1998) Differentiating turkey postvaccination isolants of Pasteurella multocida using arbitrarily primed polymerase chain reaction. Avian Dis 42: 265-274.
14. Myint A, Carter GR, (1989) Prevention of haemorrhagic septicaemia in buffaloes and cattle with a live vaccine. Vet Rec 124: 508-509.
15. Myint A, Carter GR, Jones TO, (1987) Prevention of experimental haemorrhagic septicaemia with a live vaccine. Vet Rec 120: 500-501.
16. Boyce JD, Adler B, (2001) Acapsular Pasteurella multocida B:2 can stimulate protective immunity against pasteurellosis. Infect Immun 69: 1943-1946.
17. Scott PC, Markham JF, Whithear KG, (1999) Safety and efficacy of two live Pasteurella multocida aro-A mutant vaccines in chickens. Avian Dis 43: 83-88.
18. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G, (2007) Current status of veterinary vaccines. Clin Microbiol Rev 20: 489-510.
19. APVMA (2011) Public Chemical Registration Information System. Available: http://services.apvma.gov.au/PubcrisWebClient/details.dojsessionid=rj2KTgTN2r7TX7pJ1901L0hYgWpnSBhNzg2HWQvDnGmHBLfS1zNf1548816114?view=summary&pcode=64191, Accessed 19 Oct 2011.
20. Al-Hasani K, Boyce J, McCarl VP, Bottomley S, Wilkie I, et al. (2007) Identification of novel immunogens in Pasteurella multocida. Microb Cell Fact 6: 3.
21. Hatfaludi T, Al-Hasani K, Boyce JD, Adler B, (2010) Outer membrane proteins of Pasteurella multocida. Veterinary Microbiology 144: 1-17.
22. Movahedi AR, Hampson DJ, (2008) New ways to identify novel bacterial antigens for vaccine development. Vet Microbiol 131: 1-13.
23. Rappuoli R, (2000) Reverse vaccinology. Curr Opin Microbiol 3: 445-450.
24. Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C, (1996) Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 15: 525-529.
25. Makela PH, Sibakov M, Herva E, Henrichsen J, Luotonen J, et al. (1980) Pneumococcal vaccine and otitis media. Lancet 2: 547-551.
26. Nagy G, Emody L, Pal T, (2008) Strategies for the development of vaccines conferring broad-spectrum protection. Int J Med Microbiol 298: 379-395.
27. Van Overbeke I, Chiers K, Ducatelle R, Haesebrouck F, (2001) Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. J Vet Med B Infect Dis Vet Public Health 48: 15-20.
28. May BJ, Zhang Q, Li LL, Paustian ML, Whittam TS, et al. (2001) Complete genomic sequence of Pasteurella multocida, Pm70. Proc Natl Acad Sci U S A 98: 3460-3465.
29. Wu JR, Shien JH, Shieh HK, Chen CF, Chang PC, (2007) Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE). Vaccine 25: 4140-4148.
30. Confer AW, Ayalew S, Panciera RJ, Montelongo M, Whitworth LC, et al. (2003) Immunogenicity of recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE and augmentation of a commercial vaccine. Vaccine 21: 2821-2829.
31. Pandher K, Confer AW, Murphy GL, (1998) Genetic and immunologic analyses of PlpE, a lipoprotein important in complement-mediated killing of Pasteurella haemolytica serotype 1. Infect Immun 66: 5613-5619.
32. Confer AW, Ayalew S, Panciera RJ, Montelongo M, Wray JH, (2006) Recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE enhances commercial M. haemolytica vaccine-induced resistance against serotype 6 challenge. Vaccine 24: 2248-2255.
33. Singh AP, Singh S, Ranjan R, Gupta SK, Singh VP, et al. (2010) Molecular heterogeneity of plpE gene in Indian isolates of Pasteurella multocida and expression of recombinant PlpE in vaccine strain of P. multocida serotype B: 2. J Vet Sci 11: 227-233.
34. Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, et al. (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309: 105.
35. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, et al. (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55: 687-698.
36. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, et al. (2009) Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77: 292-299.
37. Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, Masure HR, (2000) Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun 68: 5690-5695.
38. Lopez R, Garcia E, Garcia P, Garcia JL, (1997) The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb Drug Resist 3: 199-211.
39. Tatum FM, Tabatabai LB, Briggs RE, (2009) Protection against fowl cholera conferred by vaccination with recombinant Pasteurella multocida filamentous hemagglutinin peptides. Avian Dis 53: 169-174.
40. Luo Y, Glisson JR, Jackwood MW, Hancock RE, Bains M, et al. (1997) Cloning and characterization of the major outer membrane protein gene (ompH) of Pasteurella multocida X-73. J Bacteriol 179: 7856-7864.
41. Lee J, Kim YB, Kwon M, (2007) Outer membrane protein H for protective immunity against Pasteurella multocida. J Microbiol 45: 179-184.
42. Sthitmatee N, Numee S, Kawamoto E, Sasaki H, Yamashita K, et al. (2008) Protection of chickens from fowl cholera by vaccination with recombinant adhesive protein of Pasteurella multocida. Vaccine 26: 2398-2407.
43. Seib KL, Oriente F, Adu-Bobie J, Montanari P, Ferlicca F, et al. (2010) Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine 28: 2416-2427.
44. Gardy JL, Spencer C, Wang K, Ester M, Tusnady GE, et al. (2003) PSORT-B: Improving protein subcellular localization prediction for Gram-negative bacteria. Nucleic Acids Res 31: 3613-3617.
45. Lu Z, Szafron D, Greiner R, Lu P, Wishart DS, et al. (2004) Predicting subcellular localization of proteins using machine-learned classifiers. Bioinformatics 20: 547-556.
46. Juncker AS, Willenbrock H, Von Heijne G, Brunak S, Nielsen H, et al. (2003) Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci 12: 1652-1662.
47. Boyce JD, Cullen PA, Nguyen V, Wilkie I, Adler B, (2006) Analysis of the Pasteurella multocida outer membrane sub-proteome and its response to the in vivo environment of the natural host. Proteomics 6: 870-880.
48. Cabrita LD, Dai W, Bottomley SP, (2006) A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol 6: 12.
49. Birnboim HC, Doly J, (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 7: 1513-1523.
50. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al. (1995) Current protocols in molecular biology. New York, NY.: John Wiley & Sons Inc.
51. Harper M, Boyce JD, Cox AD, St Michael F, Wilkie IW, et al. (2007) Pasteurella multocida expresses two lipopolysaccharide glycoforms simultaneously, but only a single form is required for virulence: identification of two acceptor-specific heptosyl I transferases. Infect Immun 75: 3885-3893.
52. Hatfaludi T, Al-Hasani K, Dunstone M, Boyce J, Adler B, (2008) Characterization of TolC efflux pump proteins from Pasteurella multocida. Antimicrob Agents Chemother 52: 4166-4171.
53. Ge Y, Rikihisa Y, (2007) Surface-exposed proteins of Ehrlichia chaffeensis. Infect Immun 75: 3833-3841.
54. Heddleston KL, Rebers PA, (1972) Fowl cholera: cross-immunity induced in turkeys with formalin-killed in-vivo-propagated Pasteurella. Avian Dis 16: 578-586.
55. Wilkie IW, Grimes SE, O'Boyle D, Frost AJ, (2000) The virulence and protective efficacy for chickens of Pasteurella multocida administered by different routes. Vet Microbiol 72: 57-68.
56. Miller VL, Mekalanos JJ, (1988) A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol 170: 2575-2583.
57. Cardenas M, Fernandez de Henestrosa AR, Campoy S, Perez de Rozas AM, Barbe J, et al. (2001) Virulence of Pasteurella multocida recA mutants. Vet Microbiol 80: 53-61.
58. Harper M, Cox AD, St Michael F, Wilkie IW, Boyce JD, et al. (2004) A heptosyltransferase mutant of Pasteurella multocida produces a truncated lipopolysaccharide structure and is attenuated in virulence. Infect Immun 72: 3436-3443.